Amgen to open science and innovation centre in Hyderabad’s Genome Valley
The centre is expected to be operational in 2027 and will bring together discovery chemistry, drug metabolism, precision medicine, data and digital innovation as part of Amgen’s global R&D network.
Nikhil Charavarthi, Commissioner, Industries; Sarvesh Singh, CEO, Telangana Lifesciences; Krishna Aditya, Special Secretary, Industries; D. Sridhar Babu, Hon’ble Minister for IT, Electronics & Communications and Industries; Naveen Gullapalli, Managing Director, Amgen India; Srini Kosaraju, Executive Director, Amgen; and Anumita Tripathi, Director, Corporate Affairs, Amgen.
HYDERABAD: Global biotechnology company Amgen has announced plans to establish a new Science and Innovation Center at Genome Valley in Hyderabad, expanding the city’s role in the company’s global research and development network.
The centre, expected to become operational in 2027, will bring together scientists and technologists working across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine.
The new facility will become part of Amgen’s global R&D network, which currently comprises seven research laboratories. The company said the Hyderabad centre will strengthen its scientific capabilities by integrating experimental science with data and digital innovation to accelerate the discovery and development of medicines for patients worldwide.
The announcement adds another major global research presence to Hyderabad’s Genome Valley, one of India’s established life-sciences clusters.
Amgen said the new centre will work closely with its research sites around the world, enabling greater collaboration across its global scientific network and improving the speed, precision and efficiency of medicine discovery and development.
Hyderabad gains another global R&D hub
The investment strengthens Hyderabad’s position as a destination for high-value life-sciences research, particularly as pharmaceutical research increasingly converges with biotechnology, artificial intelligence, data science and advanced digital technologies.
Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen, said the Hyderabad centre would expand the company’s ability to integrate experimental science with data and technology across its global research capabilities.
According to Bradner, connecting these capabilities would allow Amgen to learn faster and translate scientific insights into innovative medicines.
The company said Genome Valley’s scientific expertise and infrastructure will complement its existing technology and innovation site in Hyderabad.
Together, the two sites are expected to enable closer integration between wet-laboratory science and technology, supporting Amgen’s efforts to develop medicines.
“This new center reflects Amgen’s commitment to advancing scientific excellence, and India will be an important part of our global R&D network,” said Som Chattopadhyay, senior vice president of Global Business Solutions and national executive at Amgen.
Focus on discovery and precision medicine
The new centre will focus on scientific disciplines that sit at the heart of modern drug discovery.
Discovery chemistry will support the identification and development of potential drug candidates, while drug metabolism and pharmacokinetics will help scientists understand how medicines behave in the body.
Precision medicine will add another dimension by using scientific and technological capabilities to support more targeted approaches to treatment.
Amgen said the Hyderabad team will work with research sites across its global network rather than operate as an isolated research facility.
That global integration is central to the company’s strategy for the new centre.
India’s role in Amgen’s global R&D network
Amgen said India will become an important part of its global R&D network through the Hyderabad expansion.
Naveen Gullapalli, managing director, Amgen India, said Hyderabad’s life-sciences ecosystem and STEM expertise would enable the company to apply advanced technologies at scale.
The Genome Valley centre will integrate biotechnology and digital innovation with the objective of serving more patients globally, he said.
The announcement also reflects the growing convergence of India’s pharmaceutical and technology capabilities.
Hyderabad already has a significant concentration of pharmaceutical, biotechnology and life-sciences companies, while Genome Valley has developed into a major research and manufacturing ecosystem.
The addition of a global R&D centre focused on advanced drug discovery and precision medicine could deepen that ecosystem by creating another link between international research networks and India’s scientific talent.
Telangana sees opportunity in high-value research
Telangana Industries and Commerce Minister D. Sridhar Babu said Amgen’s decision to establish its Science and Innovation Center in Genome Valley reflected Hyderabad’s growing role as a global hub for high-value research.
He highlighted the city’s combination of scientific talent, technology and industry and said the state’s ambition was to make Hyderabad a place where the next generation of medicines and therapies could be discovered, developed and taken to the world.
For Hyderabad, the significance of the announcement goes beyond another corporate facility.
The new centre represents the kind of high-value research activity that can strengthen the city’s position in the global life-sciences value chain — moving beyond manufacturing and services towards discovery, innovation and advanced drug development.
Science meets data and technology
Amgen’s announcement also underlines a broader transformation underway in pharmaceutical research.
Drug discovery is increasingly combining laboratory science with artificial intelligence, data analytics and other digital technologies.
The company said the new Hyderabad facility would bring together these capabilities as part of its wider effort to harness biology and technology in tackling difficult diseases.
Amgen’s global portfolio spans medicines addressing cancer, heart disease, inflammatory conditions, rare diseases and obesity-related conditions. The company says it uses biology, technology and human genetic data to advance its pipeline of medicines.
The Hyderabad centre will therefore operate at the intersection of several fast-growing areas of science — biotechnology, computational research, data, precision medicine and drug discovery.
A new chapter for Genome Valley
The centre is expected to be operational in 2027, giving Amgen time to build out the scientific and technology capabilities required for its integration into the global R&D network.
For Hyderabad, the announcement adds another global name to Genome Valley’s growing research ecosystem.
For Amgen, it provides an additional base from which to access India’s scientific and technology talent while connecting that talent to its international research infrastructure.
The larger story is the changing role of Hyderabad in global life sciences research.
Genome Valley is no longer being positioned merely as a location for pharmaceutical manufacturing. Increasingly, it is becoming a platform where scientific research, biotechnology, advanced technology and global drug-development capabilities converge.
